Silver Book Fact

After 9 years of tight blood pressure control, patients with type 2 diabetes had a 34% reduction in retinopathy progression and a 47% reduction in risk of visual acuity deterioration by three lines, when they had a 10/5 mmHg reduction in blood pressure.

Turner R, Holman R, Stratton I, Cull C, et al. Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes. BMJ. 1998; 317(7160): 703-13. http://www.bmj.com/cgi/content/abstract/317/7160/703

Reference

Title
Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes
Publication
BMJ
Publication Date
1998
Authors
Turner R, Holman R, Stratton I, Cull C, et al
Volume & Issue
Volume 317, Issue 7160
Pages
703-13
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • Omega-3 polyunsaturated fatty acids have been found to protect against the development and progression of deterioration of the retina (retinopathy).  
  • Anti-VEGF Visual Improvement
    Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.  
  • The ACCORD Eye Study found that combination lipid therapy with a fibrate and statin (compared with statin treatment alone) reduced progression of diabetic retinopathy in type 2 diabetics by around…  
  • Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients…